DPP-4 inhibitors

Case 5: Graduate Student with Atypical Symptoms

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, sulfonylureas (SUs), thiazolidinediones (TZDs)

A 25-year-old graduate student originally presented to you with symptoms of a UTI. An urinanalysis showed signs of infection, as well as glycosuria.

Continue Reading

Tailoring Clinical Practice Guidelines for Patients with Type 2 Diabetes

Posted September 21, 2011 by Sonal Singh, MD, MPH

Tags: DPP-4 inhibitors, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs)

Several guidelines emphasize the need to use existing therapeutic options to help patients and providers achieve various treatment goals, including target glycated hemoglobin levels to improve microvascular outcomes among patients with type 2 diabetes.

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett, Wendy L; Maruthur, Nisa M; Singh, Sonal; Segal, Jodi B; Wilson, Lisa M; Chatterjee, Ranee; Marinopoulos, Spyridon S; Puhan, Milo A; Ranasinghe, Padmini; Block, Lauren; Nicholson, Wanda K; Hutfless, Susan; Bass, Eric B; Bolen, Shari

Annals of internal medicine; 2011 May 3;154(9):602-13. PMID: 21403054;

Category: Interventions;

Tags: DPP-4 inhibitors, GLP-1 agonists, glycemic control, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs)

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.

Foley, J E; Bunck, M C; Möller-Goede, D L; Poelma, M; Nijpels, G; Eekhoff, E M; Schweizer, A; Heine, R J; Diamant, M

Diabetologia; 2011 Aug;54(8):1985-91. PMID: 21547496;

Category: Interventions / DPP-4s;

Tags: DPP-4 inhibitors

Can Current Drug Therapy Prevent Beta Cell Failure and Bring Treatment Durability in T2DM?

Posted July 20, 2011 by John L. Leahy, MD

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists, glycemic control, insulin therapy, metformin, prediabetes, thiazolidinediones (TZDs)

A hot topic in the type 2 diabetes world is whether we have in hand the tools to stop the decline in beta cell function that typifies this disease and, consequently, a therapy or therapies that successfully control blood glucose for many years – so-called treatment durability.

Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice.

Suarez-Pinzon, Wilma L; Lakey, Jonathan R T; Rabinovitch, Alex

Cell transplantation; 2008;17(6):631-40. PMID: 18819251;

Category: Interventions / GLP-1s;

Tags: beta cell pathophysiology, DPP-4 inhibitors

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.

Duttaroy, Alokesh; Voelker, Frank; Merriam, Kimberley; Zhang, Xia; Ren, Xianglin; Subramanian, Kala; Hughes, Thomas E; Burkey, Bryan F

European journal of pharmacology; 2011 Jan 15;650(2-3):703-7. PMID: 21070766;

Category: Interventions / DPP-4s;

Tags: DPP-4 inhibitors

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.

Maiztegui, Bárbara; Borelli, María I; Madrid, Viviana G; Del Zotto, Héctor; Raschia, María A; Francini, Flavio; Massa, María L; Flores, Luis E; Rebolledo, Oscar R; Gagliardino, Juan J

Clinical science (London, England : 1979); 2011 Jan;120(2):73-80. PMID: 20795946;

Category: Interventions / DPP-4s;

Tags: DPP-4 inhibitors

Incretin Therapy and Beta Cell Mass

Posted May 25, 2011 by Patricia Brubaker, PhD

Tags: beta cell pathophysiology, DPP-4 inhibitors, GLP-1 agonists

Analyses of human pancreata have demonstrated that type 2 diabetes is associated not only with a loss of beta cell function, but also with a marked decrease in beta cell volume.

T2DM and Fatty Liver Disease: Is What’s Good for the Gander Good for the Goose?

Posted April 7, 2011 by Kim C. Dixon, MD

Tags: DPP-4 inhibitors, GLP-1 agonists, glycemic control, lifestyle changes, metformin, sulfonylureas (SUs), thiazolidinediones (TZDs), weight

Fatty liver disease is the most common cause of chronic liver disease in North America[1] and is becoming one of the top reasons for liver transplantation. Fatty liver causes inflammation that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma.

Betacell

A resource for physicians established by the Endocrine Society

Text Size:

About Topics

Case 5: Graduate Student with Atypical Symptoms

Tailoring Clinical Practice Guidelines for Patients with Type 2 Diabetes

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.

Can Current Drug Therapy Prevent Beta Cell Failure and Bring Treatment Durability in T2DM?

Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice.

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.

Incretin Therapy and Beta Cell Mass

T2DM and Fatty Liver Disease: Is What’s Good for the Gander Good for the Goose?